zofenopril/hydrochlorothiazide ingen pharma
sia ingen pharma - zofenoprilio kalcio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 30 mg/12,5 mg - zofenopril and diuretics
zofistar plus
menarini international operations luxembourg s.a. - zofenoprilio kalcio druska/hidrochlorotiazidas - plėvele dengtos tabletės - 30 mg/12,5 mg - zofenopril and diuretics
fosinopril hct actavis
teva b.v. - fosinoprilio natrio druska/hidrochlorotiazidas - tabletės - 20 mg/12,5 mg - fosinopril and diuretics
litak
lipomed gmbh - cladribine - leukemija, plaukuotoji ląstelė - antinavikiniai vaistai - litak skirtas plaukuotųjų ląstelių leukemijai gydyti.
jayempi
nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
enalapril vitabalans
vitabalans oy - enalaprilio maleatas - tabletės - 10 mg; 5 mg; 20 mg - enalapril
amoksiklav
sandoz d.d. - amoksicilinas/klavulano rūgštis - plėvele dengtos tabletės - 500 mg/125 mg; 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor
amoksiklav
sandoz d.d. - amoksicilinas/klavulano rūgštis - milteliai injekciniam ar infuziniam tirpalui - 1000 mg/200 mg - amoxicillin and beta-lactamase inhibitor
amoksiklav
sandoz d.d. - amoksicilinas/klavulano rūgštis - disperguojamosios tabletės - 500 mg/125 mg; 875 mg/125 mg - amoxicillin and beta-lactamase inhibitor
amoksiklav
sandoz d.d. - amoksicilinas/klavulano rūgštis - milteliai geriamajai suspensijai - 400 mg/57 mg/5 ml - amoxicillin and beta-lactamase inhibitor